Tafenoquine Dosing for Malaria
For radical cure of P. vivax malaria, administer a single 300 mg dose of tafenoquine (two 150 mg tablets) on the first or second day of chloroquine therapy, taken together with food. 1
Indication and Context
Tafenoquine is indicated specifically for radical cure (prevention of relapse) of P. vivax and P. ovale malaria by eliminating dormant liver-stage hypnozoites 2. It is NOT for treating acute malaria—patients must receive concurrent chloroquine for blood-stage parasites 1.
Key Dosing Details:
- Single dose: 300 mg (two 150 mg tablets taken simultaneously)
- Timing: Administer on Day 1 or Day 2 of chloroquine therapy 1
- Administration: Take with food to increase absorption 1
- Tablets: Swallow whole—do not break, crush, or chew 1
- If vomiting occurs: Repeat dose once if vomiting within 1 hour; do not attempt re-dosing more than once 1
Critical Pre-Treatment Requirements
Mandatory G6PD Testing
All patients MUST undergo quantitative G6PD testing before prescribing tafenoquine 1. This is non-negotiable due to hemolytic anemia risk:
- Contraindicated if G6PD activity <70% of normal 2
- Contraindicated if G6PD status unknown 1
- Clinical trials excluded patients with G6PD <70% of site median 1
Pregnancy Testing
Pregnancy testing is recommended for females of reproductive potential before treatment 1, as tafenoquine may cause hemolytic anemia in a G6PD-deficient fetus 1.
Contraindications
Tafenoquine is absolutely contraindicated in:
- G6PD deficiency or unknown G6PD status 1
- Breastfeeding when infant is G6PD-deficient or has unknown G6PD status 1
- Known hypersensitivity to tafenoquine, other 8-aminoquinolines, or any component 1
- Pregnancy (not recommended due to fetal hemolysis risk) 1
Drug Combination Restrictions
Use tafenoquine ONLY with chloroquine—coadministration with other antimalarials is not recommended due to increased risk of P. vivax recurrence 1. The FDA specifically restricts tafenoquine coadministration to chloroquine only 2.
This restriction stems from clinical trial evidence showing lack of efficacy when tafenoquine was combined with dihydroartemisinin/piperaquine 1.
Evidence Base for 300 mg Dose
The 300 mg single dose was selected based on comprehensive data from 33 studies involving >4000 participants, including >800 who received the 300 mg dose 3. In the pivotal DETECTIVE trial, tafenoquine 300 mg achieved 89.2% relapse-free efficacy at 6 months (95% CI 77-95%), significantly superior to chloroquine alone (37.5%) and comparable to primaquine 15 mg for 14 days (77.3%) 4.
The hypnozoiticidal efficacy of tafenoquine 300 mg (equivalent to approximately 5 mg/kg) is estimated at 62.4% (95% CI 49.1-76.3%), while higher doses of 7.5 mg/kg achieve 87.5% efficacy 5. Despite not achieving formal non-inferiority to primaquine in some trials 6, the single-dose regimen offers critical adherence advantages over 14-day primaquine courses.
Safety Profile
The safety profile of tafenoquine 300 mg is similar to standard primaquine 3:
- Common adverse events (≥5%): Dizziness, nausea, vomiting, headache, decreased hemoglobin 1
- Hemolytic anemia: Protocol-defined hemoglobin decreases occurred in 2.4% of tafenoquine patients vs 1.2% with primaquine 6
- Vortex keratopathy: Reversible, asymptomatic corneal changes with prolonged exposure 7
- Long half-life: 15 days—psychiatric effects and hypersensitivity reactions may be delayed 1
Monitor patients for clinical signs of hemolysis even in G6PD-normal individuals, as some experienced hemoglobin declines in trials 1.
Special Populations
Lactation
Women must not breastfeed a G6PD-deficient infant or infant with unknown G6PD status for 3 months after tafenoquine dose 1, as the drug may be excreted in breast milk and cause hemolysis in G6PD-deficient infants 1.
Age Restriction
Approved only for patients ≥16 years 1.
Availability and Geographic Considerations
Tafenoquine is not available in Europe—approved only in the United States and Australia as of 2018 2. In non-endemic settings where tafenoquine is unavailable, primaquine remains the standard for radical cure.
Clinical Implementation
Recent operational data from Peru demonstrated 98.7% healthcare provider compliance with a revised radical cure algorithm incorporating quantitative G6PD testing and tafenoquine 8. This suggests the regimen is feasible to implement in routine care settings when proper G6PD testing infrastructure exists.
Community-level modeling predicts that 5 years of tafenoquine case management could reduce P. vivax transmission by 74-79% in low-prevalence settings and 17-20% in high-prevalence areas 5, though these benefits require high coverage and adherence.
Common Pitfalls to Avoid
- Never use without G6PD testing—this is the most critical safety requirement
- Do not combine with antimalarials other than chloroquine—increases recurrence risk
- Do not use for acute malaria treatment—requires concurrent blood-stage therapy
- Do not break or crush tablets—must be swallowed whole
- Do not forget food administration—significantly affects absorption
- Do not overlook breastfeeding restrictions—3-month exclusion period for at-risk infants